J&j Aids Drug Shows Promise

J&J AIDS drug shows promise

VIENNA (Reuters) - Two pivotal trials of a Johnson & Johnson experimental HIV drug found it worked as well as an existing drug, with fewer side effects but also with nearly twice as many patients failing to respond to treatment.

Sections:  news   business   living   
Topics:  aids   aids drug   drugmaker   drugs   hiv   hiv drug   johnson & johnson   side effect   
RELATED ARTICLES
  • Bayer to pay $1.1B for California firm Conceptus
    Germany drug company Bayer AG says it intends to buy California-based Conceptus to expand its birth control offerings. Bayer said Monday it would launch a pupublicblic offer to pay $31.00 per share for all the stock in Conceptus, Inc. That means Bayer would pay $1.1 billion. More
  • Cancer Physicians Attack High Drug Costs
    More than 100 cancer specialists have banded together to persuade pharmaceutical companies to bring prices down, suggesting that the high prices for medicine needed to keep someone alive is profiteering. More
  • Swedish police find drugs on Bieber tour bus
    The latest chapter in Justin Bieber's European tour escapade was added Thursday when Swedish police said they had found drugs and a stun gun on the pop singer's bus. Lars Bystrom, spokesman for the Stockholm police, told The Associated Press a small amount of drugs and a stun gun were discovered during a search of the bus, which had been parked under the Globen concert venue in Stockholm, where Bieber was performing Wednesday. More
  • Heir to Johnson & Johnson fortune dies at 76
    The family of Barbara Piasecka Johnson, a Polish farmer's daughter who worked as a maid for an American heir to the Johnson & Johnson fortune before marrying him and eventually inheriting much of his wealth, says she has died. She was 76.... More
  • AIDS Vaccine Path Suggested by Study
    By tracking one patient’s immune response, scientists have tracked how a series of mutations led to an antibody that can defeat many H.I.V. strains. More
BING NEWS:
  • J&J and Microsoft Among Defensive Stocks With Positive Earnings Outlooks
    Terence Flynn, writing from Goldman Sachs, said of the company's overall position: "J&J's diversified portfolio is a potential strength as it results in the company having the lowest exposure to ...
    07/9/2019 - 10:58 am | View Link
  • J&J-backed film about early AIDS nurses picked up for broader distribution
    RELATED: Janssen wins FDA nod for Symtuza but the once-daily HIV drug must now find its place in ... “The film is an HIV/AIDS crisis doc, commissioned by Johnson & Johnson, & shows how brands can ...
    05/10/2019 - 3:29 am | View Link
  • J&J exec: Tuberculosis is a global emergency. It's time to start treating it that way.
    Ebola, and HIV before it, shows what can be accomplished once ... claims more lives every year than HIV/AIDS — the latter being a testament to the global HIV response. Growing drug resistance has made ...
    09/26/2018 - 2:36 am | View Link
  • An Analysis Of J&J's Issues And Thoughts On Potential Ways To Maximize Shareholder Value
    Please go through the table in the linked press release with this title: It shows a shifting array of metrics ... One of them, Prezista STR, is a 4-drug product for HIV/AIDS; 3 of the 4 drugs belong ...
    10/14/2015 - 3:21 am | View Link
  • J&J Kicks Off A Pharma Earnings Season Focused On Price-Control Debate
    That’s after Turing Pharmaceuticals hiked what it charges for Daraprim—an effective drug, according to industry review, that’s used by cancer and AIDS patients ... tracked on the thinkorswim® platform ...
    10/12/2015 - 4:45 am | View Link
  • More

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News